Compare KZIA & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KZIA | MCN |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 112.7M |
| IPO Year | 2002 | 2004 |
| Metric | KZIA | MCN |
|---|---|---|
| Price | $5.61 | $5.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $28.76 | N/A |
| AVG Volume (30 Days) | ★ 167.6K | 70.1K |
| Earning Date | 11-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $5.18 |
| 52 Week High | $17.40 | $6.20 |
| Indicator | KZIA | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 26.35 | 46.09 |
| Support Level | $4.86 | $5.27 |
| Resistance Level | $14.85 | $5.71 |
| Average True Range (ATR) | 0.68 | 0.06 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 2.75 | 31.58 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.